Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Moderna, Inc. has received a consensus recommendation of "Hold" from 24 analysts, with ratings varying from four 'sell' to one 'strong buy'.
• The average one-year target price for Moderna stocks among brokerages is $43.59, while the stock is currently priced at around $27.91.
• In its recent earnings report, Moderna posted an EPS of ($2.13), exceeding expectations while also experiencing a 41.1% decline in year-over-year revenue.

Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) have earned a consensus rating of "Hold" from the twenty-four analysts that are covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, sixteen have assigned a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $43.5882.

Several research firms have weighed in on MRNA. Royal Bank Of Canada decreased their price target on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Morgan Stanley restated an "equal weight" rating and set a $32.00 price objective on shares of Moderna in a research report on Friday, August 1st. Citigroup started coverage on shares of Moderna in a research report on Friday, August 1st. They set a "neutral" rating and a $40.00 price objective on the stock. Wells Fargo & Company restated an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Finally, UBS Group decreased their price objective on shares of Moderna from $78.00 to $70.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd.

Moderna Trading Down 2.5%

MRNA stock traded down $0.67 on Wednesday, hitting $26.22. The company had a trading volume of 5,613,961 shares, compared to its average volume of 8,245,971. Moderna has a 12-month low of $23.15 and a 12-month high of $86.80. The stock's 50-day simple moving average is $29.17 and its 200 day simple moving average is $29.17. The stock has a market cap of $10.20 billion, a price-to-earnings ratio of -3.48 and a beta of 1.83.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company had revenue of $142.00 million for the quarter, compared to analysts' expectations of $116.26 million. During the same quarter last year, the company posted ($3.33) earnings per share. The firm's quarterly revenue was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. Research analysts forecast that Moderna will post -9.61 earnings per share for the current year.

Institutional Trading of Moderna

Several institutional investors and hedge funds have recently modified their holdings of the company. Marex Group plc bought a new stake in shares of Moderna during the 2nd quarter valued at $359,000. State of Wyoming purchased a new stake in Moderna in the 2nd quarter worth $94,000. Hudson Bay Capital Management LP lifted its stake in Moderna by 108.4% in the 2nd quarter. Hudson Bay Capital Management LP now owns 75,000 shares of the company's stock worth $2,069,000 after purchasing an additional 39,020 shares in the last quarter. Public Sector Pension Investment Board lifted its stake in Moderna by 45.8% in the 2nd quarter. Public Sector Pension Investment Board now owns 69,738 shares of the company's stock worth $1,924,000 after purchasing an additional 21,915 shares in the last quarter. Finally, MUFG Securities EMEA plc purchased a new stake in Moderna in the 2nd quarter worth $28,000. 75.33% of the stock is currently owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.